Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions

Boehringer Ingelheim on Friday sued the U.S. government in an attempt to block the Inflation Reduction Act’s drug price negotiation program.

The complaint, filed in a Connecticut district court, alleges that the Medicare negotiation program violates the U.S. Constitution’s Fifth Amendment right to due process and just compensation. Boehringer Ingelheim also claims that the program forces pharmaceutical companies to agree that the government’s negotiated prices are fair, thereby breaching the First Amendment.